Federal Supply Schedule 36F79718D0355
Award Date
4/1/18
Last Date to Order
9/30/25
Federal Agency
Veterans Integrated Service Network 12
Awardee
Alexion Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Alexion Pharmaceuticals Inc., a foreign-owned, for-profit biopharmaceutical company. The BPA, valued at $4,239,517.80, has a period of performance from September 1, 2022, through August 31, 2026. The primary purpose of this BPA is to provide the pharmaceutical drug Strensiq, used to treat the rare genetic disorder perinatal/infantile- and juvenile-onset...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract to BioMarin Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract has a ceiling value of $3,139,060 and runs through June 2026. Under this FSS contract, the VA has issued several delivery orders and a $151,685 Blanket Purchase Agreement (BPA) to procure the drug Palynziq (pegvaliase-pqpz) from BioMarin. The delivered Palynziq is...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple-award Federal Supply Schedule (FSS) contract to Albireo Pharma, Inc., a for-profit manufacturer of pharmaceuticals and drugs. The $225,000 contract, under the Pharmaceuticals and Drugs GSA Schedule, allows the VA's Veterans Integrated Service Network 12 to order various pharmaceutical products from Albireo Pharma over a 5-year period of performance from March 2022 to March 2027. Additionally, the VA National Acquisition Center...
This Federal Supply Schedule contract was awarded by the Veterans Integrated Service Network 12, a civilian agency of the U.S. federal government, to Alexza Pharmaceuticals, Inc., a foreign-owned for-profit manufacturing company, on August 1, 2022. The contract, awarded without any set-asides, is a multiple-award vehicle with a ceiling value of $225,000.00 and a period of performance through July 31, 2027. The contract is for the provision of 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY...
The Department of Veterans Affairs (VA) has awarded Chiesi USA Inc., a specialty pharmaceutical company, a Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This multiple-award IDV contract has a ceiling value of $27,736,880 and a period of performance through April 2026. Under this FSS contract, Chiesi USA Inc. has received several delivery orders to supply pharmaceutical products, primarily deferiprone and luspatercept, to VA medical facilities and integrated...
This Federal Supply Schedule (FSS) contract, awarded by the U.S. Department of Veterans Affairs (VA) to Alnylam Pharmaceuticals, Inc., covers the procurement of pharmaceutical and hematology-related products under FSS-61-IB. The contract has a ceiling value of $4,149,600.00 and a period of performance from February 1, 2019 to March 1, 2026. As a multiple award FSS contract, it provides a mechanism for the VA and other federal agencies to purchase a variety of pharmaceutical and drug products...
The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
The U.S. Department of Veterans Affairs (VA) has awarded a $19.3 million Federal Supply Schedule (FSS) contract to Servier Pharmaceuticals LLC, a pharmaceutical company, to provide drugs, pharmaceuticals, and hematology-related products. The contract has a period of performance through March 14, 2026. Under this FSS contract, the VA has placed multiple delivery orders for Servier's specialty oncology medications, such as pegaspargase (Oncaspar) and asparlas, to support cancer treatment...
The Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS) contract to Xeris Pharmaceuticals, Inc., a small disadvantaged business manufacturer, to provide drugs, pharmaceuticals, and hematology-related products. The contract has a ceiling value of $4,119,200 and a period of performance from July 2020 to April 2026. Under this FSS contract, the VA National Acquisition Center has issued a single award Blanket Purchase Agreement (BPA) to Xeris for the...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36F79718D0355-36E79722A0026 | Alexion Pharmaceuticals Inc. | $4.2m | 9/1/22 | 8/31/26 | 7/14/25 |
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order 36F79718D0355-36C25018F2551 | Alexion Pharmaceuticals Inc. | $24.5k | 5/7/18 | 5/31/18 | 5/7/18 | |
Delivery Order 36F79718D0355-36C25018F2937 | Alexion Pharmaceuticals Inc. | $39.2k | 6/5/18 | 7/31/18 | 6/5/18 | |
Delivery Order 36F79718D0355-36C25018F3908 | Alexion Pharmaceuticals Inc. | $58.8k | 9/17/18 | 10/12/18 | 9/17/18 | |
Delivery Order 36F79718D0355-36C25019F0648 | Alexion Pharmaceuticals Inc. | $59.8k | 1/23/19 | 4/30/19 | 3/27/19 | |
Delivery Order 36F79718D0355-36C25018F3143 | Alexion Pharmaceuticals Inc. | $19.9k | 6/30/18 | 8/31/18 | 7/17/18 |